文献速递呼吸危重症与机械通气肺栓塞与肺血管病

造血干细胞移植后弥漫性肺泡出血的流行病学、危险因素与结局

Epidemiology, Risk Factors, and Outcomes of Diffuse Alveolar Hemorrhage After Hematopoietic Stem Cell Transplantation.
PubMed 文献 · Chest · 2021-01-09

该单中心回顾性队列研究纳入2005至2016年间4350例首次造血干细胞移植患者,弥漫性肺泡出血(DAH)发生率为2.3%,自体移植1.1%、异体移植7.2%。DAH诊断后住院死亡率和1年死亡率分别为55.6%和76.8%,移植后>30天发生DAH、需有创机械通气、血小板减少和INR升高与更差结局相关。

要点

  • DAH在异体HCT后发生率为7.2%,远高于自体HCT的1.1%。
  • DAH诊断后住院死亡率55.6%,1年死亡率76.8%。
  • 移植后>30天发生DAH、需有创机械通气、血小板减少和INR升高与住院死亡风险增加相关。

核心结论

  • 造血干细胞移植后DAH死亡率仍很高,且DAH可在移植后较晚发生。
  • 移植后>30天发生DAH、需要有创机械通气、血小板减少和INR升高均与更差结局相关。

研究设计与样本

  • 单中心回顾性队列研究,纳入2005年1月1日至2016年12月31日期间接受首次造血干细胞移植的患者。
  • 共4350例首次HCT患者,其中99例(2.3%)诊断为DAH。

主要发现

  • DAH在自体HCT受者中发生40/3536例(1.1%),在异体HCT受者中发生59/814例(7.2%)。
  • DAH患者平均年龄53±13岁,DAH诊断中位时间为HCT后126天(IQR 19-349天)。
  • DAH诊断后住院死亡率为55.6%,1年死亡率为76.8%。

临床怎么用

  • 对HCT后出现DAH的患者,应评估移植后时间、血小板计数、INR及是否需要有创机械通气以判断预后。
  • 激素治疗DAH时,中等剂量(<250 mg甲泼尼龙等效/d)可能优于高剂量,但需进一步验证。

局限性

  • 单中心回顾性队列研究,结果的外推性可能受限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Diffuse alveolar hemorrhage (DAH) is an uncommon complication of hematopoietic stem cell transplantation (HCT) that carries high morbidity and mortality. Limited contemporary data are available regarding the incidence, outcomes, and risk factors for DAH. RESEARCH QUESTION: What are the incidence, outcomes, and risk factors for DAH developing after HCT? METHODS: This was a single-center retrospective cohort study of patients who underwent HCT between January 1, 2005, and December 31, 2016. The incidence and outcomes of DAH development were evaluated. A multivariate logistic regression model was used to analyze differences between survivors and nonsurvivors. RESULTS: Of 4,350 patients undergoing first-time HCT, DAH was diagnosed in 99 (2.3%). DAH was seen in 40 of 3,536 autologous HCT recipients (1.1%) and 59 of 814 allogeneic HCT recipients (7.2%). Mean age was 53 ± 13 years, and median time of DAH diagnosis was 126 days (interquartile range, 19-349 days) after HCT. In-hospital mortality and mortality 1 year after DAH diagnosis were 55.6% and 76.8%, respectively. DAH diagnosis more than 30 days after transplantation (OR, 7.06; 95% CI, 1.65-30.14), low platelet count (OR, 0.98; 95% CI, 0.96-1.0; P = .02), elevated international normalized ratio (INR; OR, 4.08; 95% CI, 0.64-25.88; P = .046) and need for invasive mechanical ventilation (OR, 8.18; 95% CI, 1.9-35.21) were associated with higher in-hospital mortality. Steroid treatment did not alter mortality (P = .80) or length of stay (P = .65). However, among those who received steroids, survival was higher in whose who received modest-dose steroids (< 250 mg methylprednisolone equivalent/d) compared with those who received high-dose steroids (≥ 250 mg methylprednisolone equivalent/d; OR, 0.21; 95% CI, 0.07-0.72). INTERPRETATION: The mortality of DAH after HCT remains high, and DAH can occur long after transplantation. Later development of DAH (>30 days after HCT), need for invasive mechanical ventilation, thrombocytopenia, and elevated INR are all associated with worse outcomes.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Zhang Z, Wang C, Peters SG, et al. Epidemiology, Risk Factors, and Outcomes of Diffuse Alveolar Hemorrhage After Hematopoietic Stem Cell Transplantation. Chest. 2021. PMID: 33434501. doi:10.1016/j.chest.2021.01.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。